Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ethenzamide→

Ethenzamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
938-73-8
Molecular formula
C9H11NO2
Molecular weight
165.19 g/mol
Drug class
Salicylamide-derived non-steroidal analgesic and antipyretic
Mechanism of action
The precise mechanism is not completely established. Ethenzamide has analgesic and antipyretic activity; experimental studies suggest spinal and central actions, including antagonism at 5-HT2B receptors. Unlike classical salicylates, it has shown little or no direct inhibition of COX-1 or COX-2 in some studies.
Indications / reported uses
  • Used as an analgesic and antipyretic, commonly in combination products, in countries where ethenzamide is authorised.

Sources: https://www.ncbi.nlm.nih.gov/mesh/67018935 · https://pubchem.ncbi.nlm.nih.gov/compound/Ethenzamide · https://www.jstage.jst.go.jp/article/bpb/43/5/43_b19-01050/_article/-char/en · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ethenzamide Environmental Risk Assessment (ERA) (the Ethenzamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.